Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.262
Sell
RSI(14)
41.528
Neutral
STOCH(KDJ)(9,3,3)
41.454
Buy
ATR(14)
0.845
Low Volatility
CCI(14)
-91.867
Neutral
Williams %R
77.077
Sell
TRIX(12,20)
-0.607
Sell
StochRSI(14)
66.265
Neutral
Search
enVVeno Medical Corp
NVNOAdd to Watchlist
9.810USD
-0.040-0.42%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
6.55MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of enVVeno Medical Corp
Currency: USD Updated: 2026-05-15Key Insights
enVVeno Medical Corp's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 215 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 12.50.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
enVVeno Medical Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
enVVeno Medical Corp Highlights
StrengthsRisks
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Overvalued
The company’s latest PE is -0.01, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 184.36K shares, decreasing 34.20% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 1.47K shares of this stock.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
12.500
Target Price
+1517.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of enVVeno Medical Corp is 5.44, ranking 358 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
2.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.39
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
enVVeno Medical Corp's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of enVVeno Medical Corp is 6.35, ranking 280 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.01, which is -4.71% below the recent high of -0.01 and -127042.35% above the recent low of -10.81.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 215/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15No earnings forecast score is currently available for enVVeno Medical Corp. The Biotechnology & Medical Research industry's average is 8.13. The average price target is 12.50, with a high of 12.50 and a low of 12.50.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
12.500
Target Price
+1517.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
enVVeno Medical Corp
NVNO
1
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of enVVeno Medical Corp is 6.93, ranking 124 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 12.50 and the support level at 8.07, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
9.752
Buy
MA10
10.005
Sell
MA20
10.959
Sell
MA50
11.008
Sell
MA100
11.011
Sell
MA200
11.766
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of enVVeno Medical Corp is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 27.61%, representing a quarter-over-quarter increase of 3.30%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of enVVeno Medical Corp is 1.44, ranking 302 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.08. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.06
VaR
+6.90%
240-Day Maximum Drawdown
+86.37%
240-Day Volatility
+405.51%
Return
Best Daily Return
60 days
+18.62%
120 days
+19.18%
5 years
+3417.00%
Worst Daily Return
60 days
-10.82%
120 days
-13.18%
5 years
-72.08%
Sharpe Ratio
60 days
+0.50
120 days
+0.19
5 years
+0.44
Risk Assessment
Maximum Drawdown
240 days
+86.37%
3 years
+89.24%
5 years
+93.24%
Return-to-Drawdown Ratio
240 days
+2.08
3 years
+0.76
5 years
+0.14
Skewness
240 days
+15.50
3 years
+26.76
5 years
+34.51
Volatility
Realised Volatility
240 days
+405.51%
5 years
+194.51%
Standardised True Range
240 days
+11.77%
5 years
+4.93%
Downside Risk-Adjusted Return
120 days
+34.42%
240 days
+34.42%
Maximum Daily Upside Volatility
60 days
+72.37%
Maximum Daily Downside Volatility
60 days
+70.86%
Liquidity
Average Turnover Rate
60 days
+0.07%
120 days
+0.96%
5 years
--
Turnover Deviation
20 days
-95.45%
60 days
-95.09%
120 days
-36.57%
Peer Comparison
Biotechnology & Medical Research
enVVeno Medical Corp
NVNO
4.14 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
